Showing results (201-210 of 228) with videos related to
Sort By:
Pageof 23
Blood Advances|April 20, 2023
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapyWilliam T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 14, 2014
Non-Hodgkin's lymphomas, version 2.2014Andrew D Zelenetz, Leo I Gordon, William G Wierda, et al.Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2012
Non-Hodgkin's Lymphomas, version 3.2012Andrew D Zelenetz, William G Wierda, Jeremy S Abramson, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015Andrew D Zelenetz, Leo I Gordon, William G Wierda, et al.The Lancet. Oncology|August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialYoun H Kim, Martine Bagot, Lauren Pinter-Brown, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2014
Non-Hodgkin's lymphomas, version 4.2014Andrew D Zelenetz, Leo I Gordon, William G Wierda, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2016
Diffuse Large B-Cell Lymphoma Version 1.2016Andrew D Zelenetz, Leo I Gordon, William G Wierda, et al.Science Translational Medicine|September 20, 2023
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependenceGongwei Wu, Noriaki Yoshida, Jihe Liu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 3, 2016
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016Steven M Horwitz, Andrew D Zelenetz, Leo I Gordon, et al.Pageof 23